# enGene Therapeutics (ENGN) — Earnings

ENGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/engn/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2025 |
| Period end | Oct 31, 2025 |
| EPS actual | −$0.73 |
| EPS estimate | −$0.57 |
| EPS surprise | −28.77% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Dec 22, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1980845/000119312525328706/engn-20251222.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2025 | Dec 22, 2025 | −$0.57 | −$0.73 | -28.77% | — | — |
| Q2 2025 | Jun 12, 2025 | −$0.50 | −$0.51 | -2.55% | — | — |
| Q1 2025 | Mar 10, 2025 | −$0.37 | −$0.48 | -30.51% | — | — |

## Frequently Asked Questions

### When did enGene Therapeutics (ENGN) last report earnings?

enGene Therapeutics last reported on Dec 22, 2025, covering fiscal Q4 2025.

### Did ENGN beat earnings estimates?

No. enGene Therapeutics reported EPS of −$0.73 for Q4 2025 against a −$0.57 estimate — a 28.77% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).